DE60321175D1 - Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten - Google Patents

Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten

Info

Publication number
DE60321175D1
DE60321175D1 DE60321175T DE60321175T DE60321175D1 DE 60321175 D1 DE60321175 D1 DE 60321175D1 DE 60321175 T DE60321175 T DE 60321175T DE 60321175 T DE60321175 T DE 60321175T DE 60321175 D1 DE60321175 D1 DE 60321175D1
Authority
DE
Germany
Prior art keywords
hemodynamic
cardioprotective
combination
cardioprotectives
dichloracetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321175T
Other languages
English (en)
Inventor
Gary D Lopaschuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Application granted granted Critical
Publication of DE60321175D1 publication Critical patent/DE60321175D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60321175T 2002-06-20 2003-06-20 Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten Expired - Lifetime DE60321175D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39070902P 2002-06-20 2002-06-20
PCT/CA2003/000929 WO2004000353A1 (en) 2002-06-20 2003-06-20 Dichloroacetate in combination with cardioprotective or hemodynamic drugs

Publications (1)

Publication Number Publication Date
DE60321175D1 true DE60321175D1 (de) 2008-07-03

Family

ID=30000603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321175T Expired - Lifetime DE60321175D1 (de) 2002-06-20 2003-06-20 Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten

Country Status (9)

Country Link
US (4) US20040039055A1 (de)
EP (1) EP1517705B1 (de)
JP (1) JP2005533796A (de)
AT (1) ATE395936T1 (de)
AU (1) AU2003278896B2 (de)
CA (1) CA2490636A1 (de)
DE (1) DE60321175D1 (de)
ES (1) ES2304521T3 (de)
WO (1) WO2004000353A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282896A1 (en) * 2002-10-07 2005-12-22 The University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope
US20060194878A1 (en) * 2002-10-07 2006-08-31 Lopaschuk Gary D Methods of cardioprotection using dichloroacetate in combination with an inotrope
WO2005077353A1 (en) * 2004-01-16 2005-08-25 The Governors Of The University Of Alberta Dichloroacetate in combination with an inotrope for cardioprotection
CN101297811A (zh) * 2007-05-04 2008-11-05 田智华 一种复方抗心律失常药
US20180071365A1 (en) * 2015-03-04 2018-03-15 Nova Southeastern University Methods and compositions for enhancing cardiac contractility for treatment of heart failure
US10478699B2 (en) 2016-04-11 2019-11-19 Brian Janssen Full scale practice and training system, method and software medium utilizing programmable chassis driven drones and tackling dummies in singular and multiple variants such as use by positional players in sole and team-based sports as well as other non-athletic training applications
US11173376B2 (en) 2016-04-11 2021-11-16 Brian Janssen Full scale practice, training and diagnostic system method and software medium including highlighted progression illuminations and field embedded pressure sensors for use by positional players in sole and team-based sports as well as other non-athletic training applications
US10441868B2 (en) 2016-04-11 2019-10-15 Brian Janssen Full scale digital replay and practice system for use by positional players in a team-based sport

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5716937A (en) * 1989-12-13 1998-02-10 The General Hospital Corporation Method for treating cardiac malfunction
CA2202397C (en) * 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
GB9410320D0 (en) * 1994-05-24 1994-07-13 Fisons Corp Novel therapeutic method
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CA2305183C (en) * 1997-10-03 2008-09-23 The Governors Of The University Of Alberta Postsurgical treatment with dichloroacetate
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6693133B1 (en) * 2002-10-07 2004-02-17 University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope

Also Published As

Publication number Publication date
AU2003278896B2 (en) 2009-10-01
ATE395936T1 (de) 2008-06-15
CA2490636A1 (en) 2003-12-31
JP2005533796A (ja) 2005-11-10
ES2304521T3 (es) 2008-10-16
US20090155240A1 (en) 2009-06-18
WO2004000353A1 (en) 2003-12-31
EP1517705B1 (de) 2008-05-21
AU2003278896A1 (en) 2004-01-06
US20120064056A1 (en) 2012-03-15
US20040039055A1 (en) 2004-02-26
EP1517705A1 (de) 2005-03-30
US20070031400A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0412411A (pt) tetrahidro-1h-pirazol[3,4-c]piridinas substituìdas, composições que as contêm e utilização
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
GB0222495D0 (en) Compounds
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
ATE516366T1 (de) Regulierte aptamer-therapeutika
DE60321175D1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20064753L (no) Kombinasjonsterapi
NO20051261L (no) Morfin-6-glukuronidsalt
SE0300457D0 (sv) Novel compounds
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
ATE520412T1 (de) Therapien für chronisch inflammatorische demyelinisierende polyradikuoneuropathie mit interferon-beta
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
EP1908462A3 (de) Dichloracetat in Kombination mit kardioprotektiven oder hämodynamischen Medikamenten

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN

8364 No opposition during term of opposition